Pacific Biosciences of California, Inc. (PACB) — Financial statements
Income statement, balance sheet, and cash flow for Pacific Biosciences of California, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 160↑3.9% | 154↓23.2% | 201↑56.3% | 128↓1.7% | 131 | |
| Cost of Revenue | 109↓6.3% | 117↓21.0% | 148↑86.4% | 79↑10.6% | 72 | |
| Gross Profit | 51↑35.9% | 37↓29.4% | 53↑7.6% | 49↓16.7% | 59 | |
| Operating Expenses | ||||||
| R&D Expenses | 97↓27.9% | 135↓27.9% | 187↓3.0% | 193↑70.9% | 113 | |
| General & Administrative Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 141↓19.2% | 175↑3.1% | 170↑5.6% | 161↑29.6% | 124 | |
| Other Expenses | 369↑83.2% | 202↑566.4% | 30↑1173.0% | 2↓92.6% | 32 | |
| Operating Expenses | 608↑18.9% | 512↑32.1% | 387↑8.7% | 356↑32.3% | 269 | |
| Total Costs & Expenses | 718↑14.2% | 628↑17.4% | 535↑22.8% | 436↑27.7% | 341 | |
| Operating Results | ||||||
| Operating Income | -558↓17.6% | -474↓41.8% | -334↓8.9% | -307↓46.0% | -210 | |
| Depreciation & Amortization | 505↑846.4% | 53↑63.2% | 33↑88.8% | 17↑49.5% | 12 | |
| EBITDA | -34↑85.9% | -243↑10.5% | -271↑3.9% | -282↓12.6% | -251 | |
| EBIT | -539↓82.1% | -296↑2.5% | -304↓1.4% | -300↓14.2% | -262 | |
| Interest & Other Income | ||||||
| Net Interest Income | -7↑48.2% | -13↑6.5% | -14↑2.4% | -15↓17.2% | -13 | |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Interest Expense | 7↓48.2% | 13↓6.5% | 14↓2.4% | 15↑17.2% | 13 | |
| Non-Operating Income | -18↑89.6% | -178↓481.4% | -31↓301.3% | -8↓114.7% | 52 | |
| Other Income / Expenses | 12↓93.0% | 165↑910.4% | 16↑331.3% | -7↑89.1% | -64 | |
| Income Before Tax | -546↓76.4% | -310↑2.7% | -318↓1.2% | -314↓14.3% | -275 | |
| Income Tax Expense | 0.32↑0.6% | 0.32↑102.8% | -11 | 0.00↑100.0% | -94 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -546↓76.3% | -310↓1.0% | -307↑2.4% | -314↓73.4% | -181 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -546↓76.3% | -310↓1.0% | -307↑2.4% | -314↓73.4% | -181 | |
| Bottom-Line Net Income | -546↓76.3% | -310↓1.0% | -307↑2.4% | -314↓73.4% | -181 | |
| EPS (Basic) | -1.82↓61.1% | -1.13↑6.6% | -1.21↑13.6% | -1.40↓57.3% | -0.89 | |
| EPS (Diluted) | -1.82↓70.1% | -1.07↑11.6% | -1.21↑13.6% | -1.40↓57.3% | -0.89 | |
| Weighted Average Shares | 300↑9.3% | 274↑8.2% | 254↑12.9% | 225↑10.3% | 204 | |
| Weighted Average Diluted Shares | 300↑4.0% | 288↑13.7% | 254↑12.9% | 225↑10.0% | 204 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.